CN101098697B - 与抑制巨噬细胞游走抑制因子有关的化合物、组合物、其制备方法和使用方法 - Google Patents

与抑制巨噬细胞游走抑制因子有关的化合物、组合物、其制备方法和使用方法 Download PDF

Info

Publication number
CN101098697B
CN101098697B CN2005800098795A CN200580009879A CN101098697B CN 101098697 B CN101098697 B CN 101098697B CN 2005800098795 A CN2005800098795 A CN 2005800098795A CN 200580009879 A CN200580009879 A CN 200580009879A CN 101098697 B CN101098697 B CN 101098697B
Authority
CN
China
Prior art keywords
alkyl
phenyl
cycloalkyl
compound
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800098795A
Other languages
English (en)
Chinese (zh)
Other versions
CN101098697A (zh
Inventor
T·西莱克
V·D·L·克鲁兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokine Pharmasciences Inc
Original Assignee
Cytokine Pharmasciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokine Pharmasciences Inc filed Critical Cytokine Pharmasciences Inc
Publication of CN101098697A publication Critical patent/CN101098697A/zh
Application granted granted Critical
Publication of CN101098697B publication Critical patent/CN101098697B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
CN2005800098795A 2004-03-26 2005-03-28 与抑制巨噬细胞游走抑制因子有关的化合物、组合物、其制备方法和使用方法 Expired - Fee Related CN101098697B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55644004P 2004-03-26 2004-03-26
US06/556,440 2004-03-26
PCT/US2005/010444 WO2005094329A2 (en) 2004-03-26 2005-03-28 Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor

Publications (2)

Publication Number Publication Date
CN101098697A CN101098697A (zh) 2008-01-02
CN101098697B true CN101098697B (zh) 2010-11-10

Family

ID=35064296

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800098795A Expired - Fee Related CN101098697B (zh) 2004-03-26 2005-03-28 与抑制巨噬细胞游走抑制因子有关的化合物、组合物、其制备方法和使用方法

Country Status (9)

Country Link
US (3) US20050250826A1 (https=)
EP (1) EP1727542A4 (https=)
JP (1) JP2007530598A (https=)
CN (1) CN101098697B (https=)
AU (1) AU2005228417A1 (https=)
BR (1) BRPI0507818A (https=)
CA (1) CA2557166C (https=)
MX (1) MXPA06010793A (https=)
WO (1) WO2005094329A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101768129B (zh) 2004-03-05 2012-05-23 日产化学工业株式会社 异*唑啉取代苯甲酰胺化合物的制备中间体
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
CA2647163C (en) * 2006-03-24 2016-06-21 The Feinstein Institute For Medical Research Modified macrophage migration inhibitory factor inhibitors
WO2008154528A2 (en) 2007-06-13 2008-12-18 E. I. Du Pont De Nemours And Company Isoxazoline insecticides
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
KR101769728B1 (ko) 2007-06-27 2017-08-18 이 아이 듀폰 디 네모아 앤드 캄파니 동물 해충 방제 방법
TWI600639B (zh) 2007-08-17 2017-10-01 杜邦股份有限公司 製備５-鹵烷基-４，５-二氫異唑衍生物之化合物
MX2010003557A (es) 2007-10-03 2010-04-12 Du Pont Compuestos de isoxazolina de naftaleno para el control de plagas de invertebrados.
TWI518076B (zh) 2008-04-09 2016-01-21 杜邦股份有限公司 製備雜環化合物之方法
US8691824B2 (en) 2008-08-04 2014-04-08 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US20130172553A1 (en) * 2009-11-25 2013-07-04 Cpsi Stockholder Trust Chiral synthesis of isoxazolines, isoxazoline compounds, and uses thereof
US20130196996A1 (en) * 2010-01-19 2013-08-01 Cpsi Stockholder Trust Use of isoxazoline compounds and compositions in bladder cancer
UA108881C2 (xx) 2010-05-27 2015-06-25 Кристалічна форма 4-$5-$3-хлор-5-(трифторметил)феніл]-4,5-дигідро-5-(трифторметил)-3-ізоксазоліл]-n-$2-оксо-2-$(2,2,2-трифторетил)аміно]етил]-1-нафталінкарбоксаміду
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
MX2014002459A (es) 2011-08-30 2014-04-10 Chdi Foundation Inc Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
TW201348214A (zh) * 2012-04-26 2013-12-01 Toyama Chemical Co Ltd 氘化含氮雜環羧醯胺衍生物
WO2013184884A1 (en) 2012-06-06 2013-12-12 Basf Corporation Improved methods for botanical and/or algae extraction
EP2944310B1 (en) 2014-05-16 2018-03-21 Mifcare MIF inhibitors for the acute or chronic treatment of pulmonary hypertension
CN106715421A (zh) 2014-07-17 2017-05-24 Chdi基金会股份有限公司 用于治疗hiv相关病症的方法和组合物
US11397182B2 (en) 2014-10-07 2022-07-26 Cornell University Methods for prognosing and preventing metastatic liver disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933464A (en) * 1988-04-25 1990-06-12 W. R. Grace & Co.-Conn. Process for forming 3-phenylisoxazolines and 3-phenylisoxazoles
JP2787602B2 (ja) * 1990-01-24 1998-08-20 大鵬薬品工業株式会社 イソキサゾリン誘導体
JP2738486B2 (ja) * 1992-11-20 1998-04-08 ファイザー製薬株式会社 抗炎症剤としての新規なイソオキサゾリン類
JPH0741459A (ja) * 1993-07-29 1995-02-10 Sumitomo Pharmaceut Co Ltd 新規エラスターゼ阻害剤
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
WO1995014680A1 (en) * 1993-11-26 1995-06-01 Pfizer Inc. 3-aryl-2-isoxazolines as antiinflammatory agents
ATE154932T1 (de) * 1993-11-26 1997-07-15 Pfizer Isoxazolinverbindungen als entzündungshemmende mittel
ATE169009T1 (de) * 1994-03-09 1998-08-15 Pfizer Isoxazoline verbindung zur hemmung tnf-freigabe
US6492428B1 (en) * 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6420188B1 (en) * 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
FR2764889B1 (fr) * 1997-06-20 2000-09-01 Sod Conseils Rech Applic Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6335445B1 (en) * 1997-03-24 2002-01-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
WO2001032606A1 (en) * 1999-10-29 2001-05-10 The Picower Institute For Medical Research Compounds having mif antagonist activity
AU2002314944B2 (en) * 2001-06-08 2008-03-06 Cytokine Pharmasciences, Inc. Isoxazoline compounds having MIF antagonist activity
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
WO2005058845A2 (en) * 2003-12-19 2005-06-30 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists

Also Published As

Publication number Publication date
JP2007530598A (ja) 2007-11-01
US20130225586A1 (en) 2013-08-29
WO2005094329A8 (en) 2006-01-05
WO2005094329A3 (en) 2007-02-08
CA2557166A1 (en) 2005-10-13
US20080113997A1 (en) 2008-05-15
WO2005094329A2 (en) 2005-10-13
MXPA06010793A (es) 2006-12-19
EP1727542A2 (en) 2006-12-06
US20050250826A1 (en) 2005-11-10
BRPI0507818A (pt) 2007-07-10
CA2557166C (en) 2015-06-30
CN101098697A (zh) 2008-01-02
AU2005228417A1 (en) 2005-10-13
EP1727542A4 (en) 2009-08-05

Similar Documents

Publication Publication Date Title
CN101098697B (zh) 与抑制巨噬细胞游走抑制因子有关的化合物、组合物、其制备方法和使用方法
CN101784532B (zh) Hiv逆转录酶抑制剂
US8759376B2 (en) Isoxazole and isothiazole compounds useful in the treatment of inflammation
US7928130B2 (en) Isoxazoline compounds having MIF antagonist activity
JP3333510B2 (ja) 抗アレルギー、抗炎症および腫瘍壊死因子抑制活性を有するシクロペンタンおよびシクロペンテン誘導体
JP7691928B2 (ja) キナーゼ阻害剤
JP2019512474A (ja) シアノ置換インドール化合物およびｌｓｄ１阻害剤としてのその使用
JP2001518094A (ja) Ｈｉｖプロテアーゼ阻害剤として有用なインダゾール−環式尿素
TW202321252A (zh) 新穎螺環吡咯啶衍生的抗病毒劑
JP2002308872A (ja) 新規ベンゾトリアゾール抗炎症化合物
TW201136918A (en) Novel substituted triazole derivatives as gamma secretase modulators
TW201121949A (en) Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
JP6334066B2 (ja) ヤヌスキナーゼ阻害剤としての置換されたＮ−（ピロリジン−３−イル）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−アミン
US20240197678A1 (en) Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1) and uses thereof
WO2017143874A1 (zh) 一种取代的恶二唑类化合物及包含该化合物的组合物及其用途
JP2010070514A (ja) ピラゾール誘導体及びその医薬用途
JP2023531008A (ja) Ｎｌｒｐ３インフラマソーム経路を調節するジヒドロオキサゾール及びチオ尿素または尿素誘導体
JP2013519727A (ja) 新規の５員複素環誘導体及びその製造方法
CN118510771A (zh) 用于治疗与呼吸道病毒感染相关联的细胞因子释放相关病症的irak抑制剂
US20070004777A1 (en) Methods for treating or preventing acute myelogenous leukemia
AU2012201680A1 (en) Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
TW201022254A (en) S1P lyase inhibitors for the treatment of cerebral malaria
AU2015201475A1 (en) Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
CN101242831A (zh) 类风湿性关节炎的预防和/或治疗方法
JPWO2007049732A1 (ja) 関節リウマチの予防及び／又は治療法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101110

Termination date: 20160328

CF01 Termination of patent right due to non-payment of annual fee